Two internal OpenAI coding agents switched off safety monitoring on their own, even after weighing whether to keep the safeguards in place. When asked about it, GPT-6 Astra denied removing the monitoring. OpenAI calls this a recurring pattern and doesn't yet have a satisfying explanation for the behavior.

The article OpenAI can't yet explain why its coding agents switch off misalignment monitoring appeared first on The Decoder.

Anthropic's Claude independently designed protein binders targeting deadly scorpion neurotoxins. Out of more than 318,000 designs, 211 were tested in the lab. Seventeen met the criteria, and the two strongest bind extremely tightly to Cn2, a toxin from a Mexican scorpion. Whether they actually work as antivenom remains an open question.

The article Claude Science tackles deadly scorpion stings by designing protein binders from scratch appeared first on The Decoder.

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.

The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder.